Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE. van der Velden DL, et al. Among authors: van berge henegouwen jm, van werkhoven e, van der wijngaart h, van herpen cml. Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30. Nature. 2019. PMID: 31570881 Clinical Trial.
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.
Ooft SN, Weeber F, Schipper L, Dijkstra KK, McLean CM, Kaing S, van de Haar J, Prevoo W, van Werkhoven E, Snaebjornsson P, Hoes LR, Chalabi M, van der Velden D, van Leerdam M, Boot H, Grootscholten C, Huitema ADR, Bloemendal HJ, Cuppen E, Voest EE. Ooft SN, et al. Among authors: van leerdam m, van werkhoven e, van der velden d, van de haar j. ESMO Open. 2021 Jun;6(3):100103. doi: 10.1016/j.esmoop.2021.100103. Epub 2021 Apr 19. ESMO Open. 2021. PMID: 33887686 Free PMC article.
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
van Berge Henegouwen JM, Jebbink M, Hoes LR, van der Wijngaart H, Zeverijn LJ, van der Velden DL, Roepman P, de Leng WWJ, Jansen AML, van Werkhoven E, van der Noort V, van der Wekken AJ, de Langen AJ, Voest EE, Verheul HMW, Smit EF, Gelderblom H. van Berge Henegouwen JM, et al. Among authors: van werkhoven e. Eur J Cancer. 2022 Aug;171:114-123. doi: 10.1016/j.ejca.2022.05.009. Epub 2022 Jun 15. Eur J Cancer. 2022. PMID: 35716537 Free article.
The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
van Brummelen EM, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH. van Brummelen EM, et al. Among authors: van werkhoven e. J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):235-42. doi: 10.1007/s10928-016-9466-0. Epub 2016 Mar 10. J Pharmacokinet Pharmacodyn. 2016. PMID: 26960536 Review.
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, van der Velden DL, van Werkhoven E, Retel VP, van Harten WH, Huitema ADR, Timmers L, Gelderblom H, Verheul HMW, Voest EE. van Waalwijk van Doorn-Khosrovani SB, et al. Among authors: van harten wh, van berge henegouwen jm, van werkhoven e, van der wijngaart h, van der velden dl, van saase l, van der graaff m. Ann Oncol. 2019 May 1;30(5):663-665. doi: 10.1093/annonc/mdz119. Ann Oncol. 2019. PMID: 31038154 Free article. No abstract available.
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.
Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, Voest EE. Cirkel GA, et al. Among authors: van werkhoven e, van stralen m. Ann Oncol. 2016 Aug;27(8):1638-43. doi: 10.1093/annonc/mdw223. Epub 2016 May 27. Ann Oncol. 2016. PMID: 27234642 Free article. Clinical Trial.
Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study.
Snoeren N, van Hillegersberg R, Schouten SB, Bergman AM, van Werkhoven E, Dalesio O, Tollenaar RA, Verheul HM, van der Sijp J, Borel Rinkes IH, Voest EE; Hepatica study group. Snoeren N, et al. Among authors: van hillegersberg r, van werkhoven e, van der sijp j. Neoplasia. 2017 Feb;19(2):93-99. doi: 10.1016/j.neo.2016.08.010. Epub 2017 Jan 12. Neoplasia. 2017. PMID: 28088688 Free PMC article. Clinical Trial.
Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids.
van der Velden DL, Cirkel GA, Houthuijzen JM, van Werkhoven E, Roodhart JML, Daenen LGM, Kaing S, Gerrits J, Verhoeven-Duif NM, Grootscholten C, Boot H, Sessa C, Bloemendal HJ, De Vos FY, Voest EE. van der Velden DL, et al. Among authors: van werkhoven e. Cancer Chemother Pharmacol. 2018 May;81(5):911-921. doi: 10.1007/s00280-018-3563-2. Epub 2018 Mar 24. Cancer Chemother Pharmacol. 2018. PMID: 29574584 Clinical Trial.
An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
de Vries Schultink AH, Alexi X, van Werkhoven E, Madlensky L, Natarajan L, Flatt SW, Zwart W, Linn SC, Parker BA, Wu AH, Pierce JP, Huitema AD, Beijnen JH. de Vries Schultink AH, et al. Among authors: van werkhoven e. Breast Cancer Res Treat. 2017 Feb;161(3):567-574. doi: 10.1007/s10549-016-4083-6. Epub 2016 Dec 22. Breast Cancer Res Treat. 2017. PMID: 28005246 Free PMC article.
136 results